N/A N=484 Parent eReferral to Tobacco Quitline
Secondhand Smoke
Primary: Number of Parent Smokers Who Enrolled in Quitline — 209; 245; 24; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=330 PRIDE: Preventing Respiratory Illnesses During Childhood Study
Tobacco Smoke Pollution
Primary: Air Nicotine Levels — 1.17; 0.58; 0.71; 0.51 mg/m^3
Phase 4 N=32 Nicotine Patch as an Adjunctive Intervention to Reduce Secondhand Smoke Among NICU Families
Environmental Tobacco Smoke · Smoking Cessation
Primary: Feasibility as Assessed by Number of Participants Who Accepted NRT Patches From Research Staff. — 13 Participants
N/A N=765 An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients
Smoking Cessation
Primary: Percentage of Participants With Self-reported Prolonged Abstinence at 6 Weeks — 4.2; 4.2 percentage of participants
N/A N=60 Health Effects of Secondhand Smoke Exposure in Outdoor Smoking Areas in Patients With COPD and Asthma ( TackSHSWP5 )
COPD · Asthma · Second Hand Tobacco Smoke
Primary: Respiratory Rate — 21.66; 21.57 BR/M breathing rate per min
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=165 NICU Asthma Education and Secondhand Smoke Reduction Study
Respiratory Illness
Primary: Infants Living in Smoke-free Environments. — 65; 64 participants
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
N/A N=396 Babies Living Safe and Smokefree
Second Hand Tobacco Smoke · Nicotine Dependence
Primary: Child Urine Cotinine — 1.00; .97; 1.09; 1.00 log transformed ng/mL
Phase 1 N=26 Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
N/A N=401 Real-Life Passive Exposure Assessment of IQOS
Environmental Exposure
Primary: NEQ: (Non-Exposure Event) — 0.03845; 4.159; 5.695; 0.06876 mg/g
N/A N=85 Assessing Toxicity of Waterpipe Tobacco Smoking
Waterpipe Smoking
Primary: Comparing Cotinine Pre-to-post Change Between 2 Waterpipe Smoking Sessions: Heating Waterpipe Tobacco by (a) Charcoal vs (b) an Electric Head — 34.9; 26.4 ng/mL — p=0.115
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=160 Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 194.05; 2314.37; 168.01 pg/mg creat — p=<0.001
N/A N=231 A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
Tobacco Use
Primary: Summary of Urine Total NNAL Amount Excreted and Absolute Change From Baseline (ng/24 Hour) by Study Group and Study Day (mITT Population) — 511.889; 581.676; 548.751…
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
N/A N=160 Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 106.25; 460.15; 91.73 pg/mg creat — p=<0.001
N/A N=296 Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products
Tobacco Use
Primary: Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) — 170.800; 174.464; 194.995; 228.143 pg/mg creatinine — p=<.0001
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=974 Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
Inflammation · Oxidative Stress · Smoking
Primary: Carboxyhemoglobin (COHb) in Blood — 3.07; 1.52; 1.49 % of CO saturated hemoglobin — p=<0.001
N/A N=68 Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
Nicotine · Vaping · Nicotine Vaping
Primary: 3-HPMA — 657.46; 726.84; 703.29; 724.06 ng/mg creatinine
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=32 Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
Smoking, Tobacco
Primary: Maximum Plasma Concentration [Cmax] — 8.425; 7.475; 13.43 ng/mL
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=67 Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
N/A N=327 Kids Safe and Smokefree (KiSS)
Second Hand Tobacco Smoke · Nicotine Dependence
Primary: Child Urine Cotinine — 0.892; 0.891 log transformed ng/mL
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=160 Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 83.21; 617.04; 83.57 pg/mg creat — p=<.001